Enesi Pharma’s ImplaVax® platform shortlisted in the Best Emerging Medtech Company Category at the OBN Awards 2020

OXFORD, UK – 9 September 2020 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been shortlisted as an OBN Awards finalist in the Best Emerging Medtech Company Category recognising the potential of our unique ImplaVax® needle free, thermally stable, immune enhancing unit solid dose vaccination technology platform that can transform the performance and delivery of vaccines and are set to make a material impact on global health.

The winner will be revealed at the 12th OBN Awards ceremony and gala dinner on 26 November in central London. The Awards celebrate outstanding achievement throughout the life sciences industry.